non-small cell lung cancer

New York, USA, June 20, 2023 (GLOBE NEWSWIRE) -- PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight The prevalence of non-small cell lung cancer has…

Ft. Myers, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- A clinical study conducted with participation by Florida Cancer Specialists & Research Institute, LLC (FCS) has led to FDA approval of a new immunotherapy that improves chemotherapy…

Hypofractionated image-guided radiotherapy (IGRT) did not improve survival compared with conventionally fractionated radiotherapy (CFRT) in…

Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC).…

Results from the first phase of the MYLUNG Consortium research study in metastatic non-small cell lung cancer (NSCLC) were released by the U.S. Oncology…

Adjuvant atezolizumab (Tecentriq) significantly improved disease-free survival compared with best supportive care after chemotherapy in patients with resected…

Patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 scores 1%-49% who received chemoimmunotherapy regimens seemed to do better than patients treated with…

The same molecular platform that led to effective vaccines against the novel coronavirus -- messenger RNA -- has begun expanding into other…

The FDA granted accelerated approval to sotorasib (Lumakras) on Friday as a second-line agent for non-small cell lung cancer (NSCLC) harboring…

Patients with early-stage non-small cell lung cancer (NSCLC) lived significantly longer without disease recurrence if they received atezolizumab (Tecentriq) after surgery and…